Outcome Measures: |
Primary: Incidence of treatment-emergent adverse events, up to 145 days|Incidence of clinically abnormal vital signs, up to 145 days|Incidence of abnormal laboratory test results, up to 145 days|Incidence of clinically abnormal physical exam, up to 145 days|Incidence of clinically abnormal electrocardiograms, up to 145 days | Secondary: Change from baseline in concentration of iron laboratory parameter, up to 145 days|Change from baseline in concentration of hematologic laboratory parameters, up to 145 days|Cmax-Maximum drug concentration measured in plasma, up to 145 days|Tmax-Time of maximum drug concentration, up to 145 days|AUC-Area under the drug concentration time curve, up to 145 days|T½ - Elimination half life of the drug, up to 145 days|CL/F-Apparent drug clearance (only for single-dose portion), up to 57 days|Vz/F; Vss/F -Apparent volume of distribution of the drug (only for single-dose portion), up to 57 days
|
Locations: |
Rocky Mountain Kidney Care - Lone Tree, Lone Tree, Colorado, 80124, United States|Accel Research, DeLand, Florida, 32720, United States|Total Research Group, Miami, Florida, 33126, United States|Flourish Research, Winter Park, Florida, 32789, United States|Nephrology and Hypertension Specialists, PC-Dalton, Dalton, Georgia, 30720, United States|Boise Kidney & Hypertension PLLC, Nampa, Idaho, 83687, United States|Center for Advanced Kidney Research PLC, Saint Clair Shores, Michigan, 48081, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Centricity Research, Columbus, Ohio, 43213, United States|Clinical Advancement Center, PLLC, San Antonio, Texas, 78212, United States|Endeavor Clinical Trials, San Antonio, Texas, 78240, United States|Washington Nephrology Associates, LLP, Alexandria, Virginia, 22304, United States
|